Amgen Inc.'s Epogen was the first biotech blockbuster drug, which helped in eliminating a condition which comprises of acute tiredness, anemia, increased risk of cardiovascular disease, and even death. At the time, the market for Epogen, which comprised dialysis patients and persons with cancer undergoing chemotherapy, was estimated to be a $1 billion chance.
After a vital scientific breakthrough, which let the EPO gene to be identified by Amgen, the business employed for quite a few patents to protect its accomplishment. However, much to its surprise, Amgen discovered that EPO had been patented. The holder of the patent, Genetics Institute, needed a royalty-free cross license. Amgen's supervisor needed to decide how best to compete with its competition.
PUBLICATION DATE: December 14, 2005 PRODUCT #: 706454-HCB-ENG
This is just an excerpt. This case is about STRATEGY & EXECUTION
Related Case Solutions & Analyses:
Note on Hiring
CP Group: Balancing the Needs of a Family Business with the Needs of a Family of Businesses
New Leadership at the Portland Public Schools
Flextronics International Ltd.
Remanufacturing: The Next Great Opportunity for Boosting U.S. Productivity
Colonial Food Services Co.
Nasdaq Japan: E-Merging Markets
Nike Inc.: Cost of Capital (v. 1.8)
Priceline.com: Name Your Own Price
San Francisco Opera
